CD274 and neoplasm: Incorporating biomarker-guided strategies, such as PD-L1 assessment or liquid biopsy monitoring of tumor and immune dynamics, may further enable precise and adaptive treatment approaches, improving both safety and efficacy in ipilimumab-based regimens [388].